Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial

• Published in: Clinical microbiology and infection Vol. 25; no. 3; pp. 365 - 371
• Main Authors: Pott-Junior, H., Bricks, G., Grandi, G., Figueiredo Senise, J., Castelo Filho, A.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.03.2019
• Subjects: Adult; Aged; Aged, 80 and over; Antiviral Agents - adverse effects; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Carbamates; Daclatasvir; Drug Therapy, Combination; Female; Genotype; Hepacivirus - drug effects; Hepacivirus - genetics; Hepatitis C; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - virology; Humans; Imidazoles - adverse effects; Imidazoles - pharmacology; Imidazoles - therapeutic use; Male; Middle Aged; Pyrrolidines; Randomized clinical trial; RNA, Viral - blood; Simeprevir; Simeprevir - adverse effects; Simeprevir - pharmacology; Simeprevir - therapeutic use; Sofosbuvir; Sofosbuvir - adverse effects; Sofosbuvir - pharmacology; Sofosbuvir - therapeutic use; Sustained Virologic Response; Valine - analogs & derivatives; Daclatasvir; Simeprevir; Randomized clinical trial; Hepatitis C; Sofosbuvir

To investigate the efficacy and safety of sofosbuvir (SOF) plus daclatasvir (DCV) or simeprevir (SMV) in a randomized, open-label, noninferiority trial of patients infected with hepatitis C virus genotype 1, who were previously unresponsive to pegylated interferon and ribavirin or were treatment nai...